NMRA Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
42.2M
-20.2%
52.9M
-9.6%
58.5M
+1.4%
57.7M
+6.8%
54.0M
R&D
29.3M
-24.1%
38.6M
-13.6%
44.7M
-1.9%
45.5M
+17.5%
38.7M
SG&A
12.9M
-9.5%
14.3M
+3.3%
13.8M
+13.4%
12.2M
-20.5%
15.3M
Operating Income
-42190000
+20.2%
-52864000
+9.6%
-58480000
-1.4%
-57700000
-6.8%
-54040000
EBITDA
-42183000
+20.2%
-52856000
+9.6%
-58471000
-1.4%
-57677000
-6.8%
-54021000
Net Income
-43082000
+19.4%
-53458000
+10.1%
-59450000
-4.7%
-56755000
-7.6%
-52731000
EPS (Basic)
$-0.23
+23.3%
$-0.30
+14.3%
$-0.35
+0.0%
$-0.35
-6.1%
$-0.33
EPS (Diluted)
$-0.23
+23.3%
$-0.30
+14.3%
$-0.35
+0.0%
$-0.35
-6.1%
$-0.33
Shares (Diluted)
185.2M
+2.9%
179.9M
+6.7%
168.6M
+4.2%
161.8M
+0.1%
161.7M
Neumora Therapeutics (NMRA) โ€” Financials